Hims & Hers Stock Soars on Strategic Pivot and Novo Nordisk Alliance

Hims & Hers partners with Novo Nordisk for FDA-approved GLP-1 drugs, resolving legal risks and fueling a 40% stock surge. The company reports strong revenue growth and global expansion plans.

Shares of the direct-to-consumer healthcare company Hims & Hers experienced a dramatic surge this week, climbing approximately 40% following a major strategic announcement. The catalyst was a decisive move away from potential legal ambiguities toward a formal, sanctioned partnership in the weight-loss medication sector.

A Clear Path Forward with a Pharma Leader

The company announced on Monday a new collaboration with pharmaceutical giant Novo Nordisk. This agreement will provide Hims & Hers users with direct access to FDA-approved GLP-1 medications, namely Wegovy and Ozempic. Concurrently, the platform is significantly scaling back the broad distribution of its own compounded semaglutid preparations. These compounded versions will now be reserved strictly for use in exceptional medical circumstances where commercially available drugs are not suitable.

Investors responded with overwhelming positivity to the resolution of looming patent dispute risks, a concern that had previously weighed on the stock's valuation. The share price jumped from around $16.50 to over $23.10 within the week, reflecting market relief at the diminished regulatory uncertainty.

Robust Financial Performance Amid a Margin Shift

This strategic shift comes during a period of strong operational execution. For the completed fiscal year 2025, Hims & Hers reported revenue of $2.35 billion, representing year-over-year growth of 59%. The company achieved a net profit of $128.4 million and now serves 2.5 million active subscribers.

One noted aspect of the financials was a dip in gross margin to 72%. This contraction is directly tied to the ongoing transition toward lower-margin, high-volume branded weight-loss drugs. However, the market largely overlooked this margin pressure, focusing instead on the company's sustained profitability and newly stabilized regulatory footing.

Building for Global Growth

Looking ahead, management is investing heavily in infrastructure, including pharmacy operations and laboratory capabilities, to support future expansion. For the first quarter of 2026, revenue is projected to land between $600 million and $625 million. The full-year outlook calls for sales in the range of $2.7 billion to $2.9 billion.

The company is also actively extending its international reach. The recent acquisition of the digital health platform Eucalyptus provides a gateway into key markets such as Australia, the United Kingdom, and Germany. This move, coupled with the Tuesday appointment of new Chief Communications Officer Kathryn Beiser and the launch of a new user discount program, positions the company structurally for its next phase of global growth.